Insider Selling: Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Sells 37,500 Shares of Stock

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPIGet Rating) major shareholder Global Strategic Fund I. Venbio sold 37,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 4th. The shares were sold at an average price of $10.37, for a total value of $388,875.00. Following the completion of the transaction, the insider now directly owns 2,535,158 shares in the company, valued at approximately $26,289,588.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of CMPI stock opened at $10.37 on Thursday. Checkmate Pharmaceuticals, Inc. has a fifty-two week low of $2.00 and a fifty-two week high of $10.48. The stock’s fifty day moving average price is $4.81 and its two-hundred day moving average price is $3.79.

Checkmate Pharmaceuticals (NASDAQ:CMPIGet Rating) last released its quarterly earnings data on Tuesday, March 29th. The company reported ($0.62) earnings per share for the quarter. On average, analysts forecast that Checkmate Pharmaceuticals, Inc. will post -3.14 earnings per share for the current year.

A hedge fund recently bought a new stake in Checkmate Pharmaceuticals stock. Millennium Management LLC acquired a new position in shares of Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPIGet Rating) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 10,633 shares of the company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 74.56% of the company’s stock.

Several equities analysts have recently commented on CMPI shares. BTIG Research downgraded Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, April 20th. Zacks Investment Research upgraded Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday.

About Checkmate Pharmaceuticals (Get Rating)

Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.

See Also

Insider Buying and Selling by Quarter for Checkmate Pharmaceuticals (NASDAQ:CMPI)

Receive News & Ratings for Checkmate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkmate Pharmaceuticals and related companies with's FREE daily email newsletter.